Primary study objective: To study the effect of efavirenz on the pharmacokinetics of SHR1459 in healthy subjects. Secondary study objective: To observe the safety of single administration of SHR1459, multiple administration of efavirenz, and combination administration of the two drugs in healthy subjects.

Start Date04 Nov 2022

Sponsor / Collaborator

Shanghai Hengrui Pharmaceutical Co., Ltd.

[+1]

CTR20211415

/ CompletedPhase 1

[ 14C]SHR1459在中国成年男性健康受试者体内的单中心、单剂量、非随机、开放的吸收、代谢和排泄临床试验

[Translation] A single-center, single-dose, non-randomized, open-label clinical trial of the absorption, metabolism, and excretion of [14C]SHR1459 in healthy adult male subjects in China

主要研究目的： 1) 考察中国成年男性健康受试者单次口服[ 14C]SHR1459 后全血和血浆中的分配情况和血浆中总放射性的药代动力学； 2) 定量分析男性健康受试者口服[ 14C]SHR1459 后排泄物中的总放射性，获得人体放射性回收率数据和主要排泄途径； 3) 鉴定男性健康受试者口服[ 14C]SHR1459 后人体内的主要代谢产物，确定主要生物转化途径和主要代谢产物（>10%总放射性 AUC）； 4) 采用已验证的液相色谱串联质谱联用法（LC-MS/MS）定量分析血浆中 SHR1459 和主要代谢产物，获得相应药动学参数（代谢产物如适用）；次要研究目的： 5) 观察[ 14C]SHR1459 单次给药后中国成年男性健康受试者的安全性。

[Translation]

The main study objectives are: 1) To investigate the distribution of [14C]SHR1459 in whole blood and plasma and the pharmacokinetics of total radioactivity in plasma in healthy Chinese adult male subjects after a single oral administration. 2) To quantitatively analyze the total radioactivity in the excreta of healthy male subjects after oral administration of [14C]SHR1459, and obtain the data on the recovery rate of human radioactivity and the main excretion pathway. 3) To identify the main metabolites of [14C]SHR1459 in the human body after oral administration of healthy male subjects, and determine the main biotransformation pathways and main metabolites (>10% of the total radioactivity AUC). 4) To quantitatively analyze SHR1459 and major metabolites in plasma using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method to obtain the corresponding pharmacokinetic parameters (metabolites if applicable). Secondary study objectives: 5) To observe the safety of [14C]SHR1459 in healthy Chinese adult male subjects after a single dose.

Start Date07 Jun 2022

Sponsor / Collaborator

Shanghai Hengrui Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Edralbrutinib

100 Translational Medicine associated with Edralbrutinib

100 Patents (Medical) associated with Edralbrutinib

Literatures (Medical) associated with Edralbrutinib

01 Dec 2021·Clinical Cancer ResearchQ1 · MEDICINE

Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma

Q1 · MEDICINE

Article

Author: Normant, Emmanuel ; Sedó Mor, Alícia ; Ribeiro, Marcelo Lima ; Blecua, Pedro ; Esteller, Manel ; Musulen, Eva ; Armengol, Marc ; Reyes-Garau, Diana ; Bosch, Francesc ; Profitós Pelejà, Núria ; Menéndez, Pablo ; Miskin, Hari ; Roué, Gaël ; Bech-Serra, Joan J. ; Vinyoles, Meritxell ; Fernández-Serrano, Miranda ; Santos, Juliana Carvalho ; De La Torre, Carolina

AbstractPurpose:Despite the remarkable activity of BTK inhibitors (BTKi) in relapsed B-cell non–Hodgkin lymphoma (B-NHL), no clinically-relevant biomarker has been associated to these agents so far. The relevance of phosphoproteomic profiling for the early identification of BTKi responders remains underexplored.Experimental Design:A set of six clinical samples from an ongoing phase I trial dosing patients with chronic lymphocytic leukemia (CLL) with TG-1701, a novel irreversible and highly specific BTKi, were characterized by phosphoproteomic and RNA sequencing (RNA-seq) analysis. The activity of TG-1701 was evaluated in a panel of 11 B-NHL cell lines and mouse xenografts, including two NF-κB- and BTKC481S-driven BTKi-resistant models. Biomarker validation and signal transduction analysis were conducted through real-time PCR, Western blot analysis, immunostaining, and gene knockout (KO) experiments.Results:A nonsupervised, phosphoproteomic-based clustering did match the early clinical outcomes of patients with CLL and separated a group of “early-responders” from a group of “late-responders.” This clustering was based on a selected list of 96 phosphosites with Ikaros-pSer442/445 as a potential biomarker for TG-1701 efficacy. TG-1701 treatment was further shown to blunt Ikaros gene signature, including YES1 and MYC, in early-responder patients as well as in BTKi-sensitive B-NHL cell lines and xenografts. In contrast, Ikaros nuclear activity and signaling remained unaffected by the drug in vitro and in vivo in late-responder patients and in BTKC481S, BTKKO, and noncanonical NF-κB models.Conclusions:These data validate phosphoproteomic as a valuable tool for the early detection of response to BTK inhibition in the clinic, and for the determination of drug mechanism of action.

News (Medical) associated with Edralbrutinib

19 Sep 2024

·www.prnewswire.com

Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and immunotherapies, such as Bruton's tyrosine kinase (BTK) inhibitors, is improving treatment outcomes and driving market growth for Mantle cell lymphoma. LAS VEGAS, Sept. 19, 2024 /PRNewswire/ -- DelveInsight's ' Mantle Cell Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline mantle cell lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the mantle cell lymphoma pipeline domain. Key Takeaways from the Mantle Cell Lymphoma Pipeline Report DelveInsight's mantle cell lymphoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for mantle cell lymphoma treatment. Key mantle cell lymphoma companies such as AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others are evaluating new mantle cell lymphoma drugs to improve the treatment landscape. Promising mantle cell lymphoma pipeline therapies such as Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under different phases of mantle cell lymphoma clinical trials. In May 2024, AstraZeneca had announced positive interim results from the Phase III ECHO clinical trial, which evaluated Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in combination with standard chemoimmunotherapy for treating mantle cell lymphoma (MCL). In March 2024, BeiGene, Ltd. announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting. Additional highlights include preclinical characterization data for an investigational BTK degrader, BGB-16673, currently in clinical development for B-cell malignancies, including mantle cell lymphoma In October 2023, Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment. The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor, CALQUENCE® (acalabrutinib), in treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In January 2023, the FDA granted an orphan drug designation to LP-284, a novel small-molecule, next-generation acylfulvene, for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of B-cell non-Hodgkin lymphoma (NHL), according to an announcement from Lantern Pharma. Request a sample and discover the recent advances in mantle cell lymphoma treatment drugs @ Mantle Cell Lymphoma Pipeline Report The mantle cell lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mantle cell lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the mantle cell lymphoma clinical trial landscape. Mantle Cell Lymphoma Overview Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by the (11,14) translocation, leading to overexpression of the cyclin D1 (CCND1) gene. Its various morphological variants can make diagnosis challenging, though some cases are straightforward. Many individuals with MCL are asymptomatic in the early stages, but may later seek medical attention due to persistent, typically painless swelling of lymph nodes, especially in the neck and throat region (e.g., Waldeyer's ring). MCL is marked by a reciprocal chromosomal translocation t(11;14)(q13;q32), which places the cyclin D1 gene next to the immunoglobulin heavy chain gene, causing continuous cyclin D1 expression. This overexpression contributes to tumor cell proliferation through cell cycle dysregulation, chromosomal instability, and epigenetic changes. Rarely, MCL cases without this translocation may involve CCND2 or CCND3 translocations. Hypothetical molecular subtypes, based on the cell of origin, correlate with clinical phenotypes: classical or aggressive MCL arises from naive B cells lacking or having limited iGVH mutations and expressing SOX11, a neural transcription factor inhibiting terminal B cell differentiation. The indolent variant originates from antigen-experienced B cells with IGVH somatic hypermutations, typically SOX11-negative and genetically stable. Diagnosis of MCL involves detailed patient history, thorough clinical evaluation, and specialized tests, including biopsy of an affected lymph node or bone marrow. These tests confirm the NHL type and subtype, assess disease extent, and determine appropriate treatments. Treatment for MCL is multifaceted and tailored to each patient, often including chemotherapy, immunotherapy drugs like rituximab, targeted therapies such as ibrutinib, and stem cell transplants, particularly for aggressive disease or younger patients. Radiation therapy may target specific lymphoma areas. Participation in clinical trials can offer new treatment options. Treatment plans are developed collaboratively by healthcare professionals and patients, considering disease stage, overall health, and personal preferences. Regular monitoring and follow-up care are essential to track treatment response and manage side effects effectively. Find out more about mantle cell lymphoma treatment drugs @ Drugs for Mantle Cell Lymphoma Treatment A snapshot of the Mantle Cell Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging mantle cell lymphoma pipeline therapies @ Mantle Cell Lymphoma Clinical Trials Mantle Cell Lymphoma Therapeutics Assessment The mantle cell lymphoma pipeline report proffers an integral view of the mantle cell lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Mantle Cell Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors, Proteasome inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Agammaglobulinemia tyrosine kinase inhibitors Key Mantle Cell Lymphoma Companies: AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others Key Mantle Cell Lymphoma Pipeline Therapies: Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others Dive deep into rich insights for new drugs for mantle cell lymphoma treatment, visit @ Mantle Cell Lymphoma Drugs Table of Contents For further information on the mantle cell lymphoma pipeline therapeutics, reach out @ Mantle Cell Lymphoma Treatment Drugs Related Reports B-Cell Lymphoma Epidemiology B-Cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the B-cell lymphoma epidemiology trends. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Pipeline Diffuse Large B-Cell Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3ImmunotherapyOrphan Drug

01 Jun 2023

·www.prnewswire.com

Idiopathic Membranous Nephropathy Market to Register Immense Growth at a CAGR of 12% During the Study Period (2019-2032), Predicts DelveInsight

As potential therapies are being investigated to manage idiopathic membranous nephropathy, it is safe to predict that the idiopathic membranous nephropathy market will experience significant reconstitution during 2023–2032. However, the challenges of the rigid and burdensome structure of regulatory authorities will decide the fate of all these pipeline therapies and the impact they will have on overall revenue generation. LAS VEGAS, June 1, 2023 /PRNewswire/ -- DelveInsight's Idiopathic Membranous Nephropathy Market Insights report includes a comprehensive understanding of current treatment practices, idiopathic membranous nephropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] and China. Key Takeaways from the Idiopathic Membranous Nephropathy Market Report As per DelveInsight analysis, the idiopathic membranous nephropathy market size in the 7MM + China was approximately USD 220 million in 2022. According to the assessment done by DelveInsight, the estimated total prevalent idiopathic membranous nephropathy cases in the 7MM + China were approximately 380K in 2022. Leading idiopathic membranous nephropathy companies such as Hoffmann-La Roche, MorphoSys, Cerium Pharmaceuticals, BeiGene, Reistone Biopharma, Eternity Bioscience, GlaxoSmithKline, ValenzaBio, ACELYRIN, and others are developing novel Idiopathic Membranous Nephropathy drugs that can be available in the Idiopathic Membranous Nephropathy market in the coming years. The promising idiopathic membranous nephropathy therapies in the pipeline include GAZYVA (obinutuzumab), MOR202 (felzartamab), SNP-ACTH (1-39) Gel, BRUKINSA (zanubrutinib), SHR1459 (edralbrutinib), BENLYSTA (belimumab), VB119 , and others. Discover which therapies are expected to grab the major idiopathic membranous nephropathy market share @ Idiopathic Membranous Nephropathy Market Report Idiopathic Membranous Nephropathy Overview Membranous nephropathy is a kidney disease affecting the kidney's filters. It causes a rise in protein in the urine, impaired renal function, and edoema. It's also known as membranous glomerulopathy. Membranous nephropathy is a rare disease that affects the renal glomerulus, specifically the podocytes, which play an important role in limiting the permeability of the kidney to proteins. The most common membranous nephropathy symptom is swelling, often known as edema. This might range from minor to severe. Most patients have some edema, which is generally the initial symptom. Swelling in membranous nephropathy is usually slow compared to other disorders that cause protein in the urine and nephrotic syndrome, but it can sometimes be sudden. It usually begins in the feet, ankles, or legs, although it can develop elsewhere in the body, including the abdomen, hands, arms, and face. Protein in the urine is frequently used to make membranous nephropathy diagnosis. A blood test, a kidney biopsy, optical microscopy, immunofluorescence, electron microscopy, and antibody-guided diagnostics are also conducted. Idiopathic Membranous Nephropathy Epidemiology Segmentation DelveInsight estimates that there were approximately 380K prevalent cases of idiopathic membranous nephropathy in the 7MM in 2022. China contributed to the largest prevalent population of idiopathic membranous nephropathy, acquiring ~82% of the 7MM and China in 2022. Whereas EU4 and the UK for ~6%, and Japan accounted for ~ 5% of the total population share, in 2022. The idiopathic membranous nephropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM + China segmented into: Idiopathic Membranous Nephropathy Prevalence Idiopathic Membranous Nephropathy Prevalence by Antigens Idiopathic Membranous Nephropathy Treatment Market There is no cure for either primary or secondary membranous nephropathy. When treating individuals with the illness, doctors usually take a symptomatic approach and aim to improve the patient's immune system. Patients are put on supportive care as soon as the diagnosis is confirmed, regardless of the underlying cause, and this is continued throughout the duration of the condition. It includes careful blood pressure control, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce proteinuria and increase the chances of spontaneous remission, statins for hyperlipidemia, salt restriction, diuretics to control edoema, and a low protein diet to allow for the replacement of urinary protein losses. In recent research, alkylating drugs used in combination with corticosteroids produced positive results in membranous nephropathy patients. Immunosuppressive therapy (such as steroids and alkylating agents, calcineurin inhibitors (CNIs), and rituximab) are among the medications used to treat membranous nephropathy patients. Alkylating drugs, steroids, and calcineurin inhibitors (CNIs) have formed the foundation of immunosuppression and immunosuppressive medications. Though they are partially effective in reducing proteinuria in membranous nephropathy patients, they have also been linked to greater relapse rates and significant adverse responses. To know more about idiopathic membranous nephropathy treatment guidelines, visit @ Idiopathic Membranous Nephropathy Management Idiopathic Membranous Nephropathy Pipeline Therapies and Key Companies GAZYVA (obinutuzumab): Hoffmann-La Roche MOR202 (felzartamab): MorphoSys SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals BRUKINSA (zanubrutinib): BeiGene SHR1459 (edralbrutinib): Reistone Biopharma/Eternity Bioscience BENLYSTA (belimumab): GlaxoSmithKline VB119: ValenzaBio/ACELYRIN Learn more about the FDA-approved drugs for idiopathic membranous nephropathy @ Drugs for Idiopathic Membranous Nephropathy Treatment Idiopathic Membranous Nephropathy Market Dynamics The dynamics of the idiopathic membranous nephropathy market are expected to change in the coming years. Increased research activities and the discovery of new biomarkers and therapeutic targets, will result in the development of improved medicines in the future. Although rituximab is effective, patients can acquire medication resistance over time. Roche's Obinutuzumab is being developed with improved efficacy, which will aid in overcoming the limits of current therapy. Moreover, the rapid incidence of progression and remission in membranous nephropathy patients provides pharmaceutical companies with an opportunity to develop therapies to address the inadequacies and capture a largely untapped idiopathic membranous nephropathy market. Only a few drugs, such as Obinutuzumab, are in the latter stages of development. As a result, it opens the door for additional pharmaceutical companies to enter the idiopathic membranous nephropathy market with fresh therapeutic choices. However, several factors may impede the growth of the idiopathic membranous nephropathy market. Due to knowledge gaps and a lack of clarity about membranous nephropathy pathology, there is an urgent scarcity of large-scale clinical studies assessing therapy alternatives in membranous nephropathy. The outcomes of idiopathic membranous nephropathy treatment candidates that are in various stages of clinical development and are expected to be launched are not available. As a result, establishing the safety and efficacy of these medications is difficult. Moreover, as membranous nephropathy is a rare indication, it is often overshadowed by more common and fatal renal diseases, thereby influencing the whole research and development process. Almost 30% of membranous nephropathy cases develop into ESRD, yet the therapeutic landscape is devoid of recognized medicines, leading to a high fatality rate. Scope of the Idiopathic Membranous Nephropathy Market Report Therapeutic Assessment: Idiopathic Membranous Nephropathy current marketed and emerging therapies Idiopathic Membranous Nephropathy Market Dynamics: Attribute Analysis of Emerging Idiopathic Membranous Nephropathy Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Idiopathic Membranous Nephropathy Market Access and Reimbursement Discover more about idiopathic membranous nephropathy drugs in development @ Idiopathic Membranous Nephropathy Clinical Trials Table of Contents Related Reports Idiopathic Membranous Nephropathy Epidemiology Forecast Idiopathic Membranous Nephropathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and idiopathic membranous nephropathy epidemiology trends. Nephrotic Syndrome Pipeline Nephrotic Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nephrotic syndrome companies, including GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, among others. Nephrotic Syndrome Market Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nephrotic syndrome companies, including GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

05 Aug 2021

·www.globenewswire.com

A Robust Neuromyelitis Optica Spectrum Disorder Pipeline Domain Witnesses Several Novel and Promising Therapies in Different Stages of Clinical Development Expected to Enter the Market by the Next Dec

Los Angeles, USA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A Robust Neuromyelitis Optica Spectrum Disorder Pipeline Domain Witnesses Several Novel and Promising Therapies in Different Stages of Clinical Development Expected to Enter the Market by the Next Decade DelveInsight’s analysis demonstrates a robust Neuromyelitis Optica Spectrum Disorder Pipeline with 15+ active players in the domain working on 15+ pipeline therapies. DelveInsight’s ‘Neuromyelitis Optica Spectrum Disorder Pipeline Insights’ report presents an exhaustive coverage of the available therapies, Neuromyelitis Optica Spectrum Disorder emerging therapies in different phases of clinical development, key companies working in the Neuromyelitis Optica Spectrum Disorder pipeline domain, and future potential of the space. Some of the notable pointers extracted from the Neuromyelitis Optica Spectrum Disorder Pipeline report: Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Neuromyelitis Optica Spectrum Disorder Emerging Therapies and Forecast The Neuromyelitis Optica Spectrum Disorder Pipeline reports lays down a comprehensive structure of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Neuromyelitis Optica Spectrum Disorder domain. Neuromyelitis Optica Spectrum Disorder Overview Neuromyelitis Optica Spectrum Disorder (NMOSD), also referred to as Devic disease, is a chronic condition that causes inflammation of the optic nerve and spinal cord thereby affecting the brain and spinal cord. The condition is an autoimmune disorder, however, the exact pathophysiology and cause of the autoimmunity remain unclear. Discover more about the disease, treatments, and pipeline therapies @ NMOSD Pipeline Assessment Neuromyelitis Optica Spectrum Disorder Pipeline Drugs Request for Sample to know more @ Neuromyelitis Optica Spectrum Disorder Pipeline Analysis, Key Companies, and Futuristic Trends Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment The Neuromyelitis Optica Spectrum Disorder Pipeline report presents a holistic picture of the Neuromyelitis Optica Spectrum Disorder emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets For rich insights into merging therapies and assessment, visit NMOSD Pipeline Emerging Novel Therapies Scope of the Neuromyelitis Optica Spectrum Disorder Pipeline Report Coverage: GlobalKey Players: Alexion Pharmaceuticals, RemeGen, Reistone Biopharma, Chord Therapeutics, Nihon Pharmaceuticals, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, Boston Pharmaceuticals, and TG Therapeutics among others.Key Neuromyelitis Optica Spectrum Disorder Pipeline Therapies: Ravulizumab, Telitacicept, SHR1459, CRD1, HBM9161, BAT4406F, ABX-1431, BN201, ARN-6039, and Ublituximab among others.Discover more about the scope of the report @ Neuromyelitis Optica Spectrum Disorder Emerging Therapies, Treatments, and Ongoing Clinical Trials Table of Contents Learn more about the report offerings @ Neuromyelitis Optica Spectrum Disorder Pipeline Therapies and Emerging Trends Audit the market before venturing with DelveInsight’s Due Diligence Services Related Reports Neuromyelitis Optica Spectrum Disorder MarketDelveInsight's "Neuromyelitis Optica Spectrum Disorder (Neuromyelitis Optica Spectrum Disorder) Market Insights, Epidemiology and Market Forecast-2028" report. Pompe Disease Market Insight Epidemiology And Market ForecastDelveInsight's "Pompe Disease Market Insights, Epidemiology and Market Forecast-2028" report. Spinal Muscular Atrophy Sma Market Insight Epidemiology And Market ForecastDelveInsight's 'Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast-2028' report. Spinocerebellar Ataxias Market Insights Epidemiology And Market ForecastDelveInsight's 'Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast-2028’ report. Acute Ischemic Stroke Market InsightsDelveInsight’s ‘Acute Ischemic Stroke (AIS) - Market Insights, Competitive Landscape and Market Forecast–2026’ report. Adult Intraventricular Hemorrhage MarketDelveInsight’s ‘Adult Intraventricular Haemorrhage Market Insights, Competitive Landscape and Market Forecast-2026’ report. Carotid Stenotic Scan Devices MarketDelveInsight’s ‘Carotid Stenotic Scan Devices Market Insights, Competitive Landscape and Market Forecast-2026’ report. Browse through our posts Dynamics Of Schizophrenia MarketAlzheimer’s Disease Market LandscapeAdvancements in Neuromodulation in the Neurological Disorders MarketDeep Brain Stimulation Devices and Changing Market Landscape About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

100 Deals associated with Edralbrutinib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic Membranous Glomerulonephritis	Phase 2	CN	Reistone Biopharma Co. Ltd.Startup	10 Dec 2021
Chronic Lymphocytic Leukemia	Phase 2	PL	TG Therapeutics, Inc.	10 Sep 2018
Chronic Lymphocytic Leukemia	Phase 2	AU	TG Therapeutics, Inc.	10 Sep 2018
B-cell lymphoma recurrent	Phase 2	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Glomerulonephritis, Membranous	Phase 2	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Neuromyelitis Optica	Phase 2	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Rheumatoid Arthritis	Phase 1	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	04 Sep 2018
B-Cell Leukemia	Phase 1	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Feb 2018
Refractory Mature B-Cell Non-Hodgkin Lymphoma	Phase 1	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Feb 2018
B-cell lymphoma refractory	Discovery	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03671590 (TG-1701, ICML2021)	Phase 1	B-Cell Lymphoma	123	TG-1701 monotherapy	vbjajtwqto(tfhgpwityv) = etdybtbkqb dcoiiutvpr (hqnlfygcfr ) View more	Positive	17 Jun 2021
				TG-1701+U2 combination	(smxantfrew) = dlyjdwfxck bsokkplkyl (yogqrqqufq ) View more
NCT03671590 (TG-1701, EHA2021)	Phase 1	Chronic Lymphocytic Leukemia \| Lymphoma	123	TG-1701 monotherapy	(ueqwqdldgi) = ohwhrfriye ijnletpkee (kwixlvcwvf ) View more	-	09 Jun 2021
				TG-1701+U2 combination	(lbnqpibden) = cxpesjxahd bfrifftwfo (uofkoqdrxq )
NCT03671590 (ASCO2021)	Phase 1	Chronic Lymphocytic Leukemia	123	TG-1701 monotherapy	(bdizcgzaob) = TEAEs leading to TG-1701 dose reduction occurred in 6.5% of pts. TEAEs leading to treatment discontinuation occurred in 1.6% of pts (AF, COVID-19) gvibnrxrzv (kfoqlwrhmn )	-	28 May 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis